Intriguingly, decreased Lyn levels significantly reduced Claudin-2 expression in human (Figure 4D) and mouse triple-negative breast cancer cells (Supplementary Figure 3C). This evidence concerns the gene CLDN2 and triple-negative breast carcinoma.